Document is current
Any future updates will be listed below
-
Authors
King, Joseph A.
Bernardoni, Fabio
Westbrook, Andrew
Korb, Franziska M. https://orcid.org/0000-0002-1005-0090
Boehm, Ilka
Doose, Arne
Geisler, Daniel
Gramatke, Katrin
Hellerhoff, Inger
Wolff, Sylvia
Strobel, Alexander
Goschke, Thomas
Roessner, Veit
Ehrlich, Stefan https://orcid.org/0000-0003-2132-4445
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB 940, SFB 940, SFB 940, SFB 940, SFB 940, SFB 940, SFB 940, SFB 940)
https://www.bayer-foundation.com/de
- License Information
-
More Information
Article History
Received: 22 December 2023
Revised: 16 August 2024
Accepted: 21 August 2024
First Online: 28 August 2024
Competing interests
: IH has received a scholarship from the Bayer Foundation. VR has received payment for consulting and writing activities from Lilly, Novartis, and Shire Pharmaceuticals, lecture honoraria from Lilly, Novartis, Shire Pharmaceuticals, and Medice Pharma, and support for research from Shire and Novartis. He has carried out (and is currently carrying out) clinical trials in cooperation with the Novartis, Shire, and Otsuka companies. Funding sources were not involved in the design of the study, the collection and analysis of data, or the decision to publish. Other authors declare no competing interests.
: This study was carried out in accordance with the Declaration of Helsinki and approved by the ethics committee of the Technische Universität Dresden (EK 536122015). All participants (or their legal guardians) gave written informed consent.
